3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Advanced Solid Tumours
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Endometrial Neoplasms
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Carboplatin
6
Pemetrexed
5
pembrolizumab
3
selpercatinib
2
pralsetinib
2
osimertinib
2
durvalumab
2
camrelizumab
2
Cisplatin
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
belinostat
1
belagenpumatucel L
1
alectinib
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oncolytic Virotherapy
1
Injections
1
Gemcitabine
1
Fluorouracil
1
Erlotinib Hydrochloride
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Bronchogenic
×
ceralasertib
×
Clear all
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled